Kaplan-Meier curves for OS in 172 patients with intermediate-risk cytogenetics stratified by status. (A) TET2 mutation and FLT3-ITD. (B) TET2 and NPM1 mutations. The OS was also stratified by the status of TET2 mutation in patients with favorable molecular genotypes (NPM1⁺/FLT3-ITD⁻ or CEBPA^double; C) and in patients without these favorable genotypes (D). Both the genotypes TET2⁺/FLT3-ITD⁺ and TET2⁺/NPM1⁻ are independent unfavorable factors for OS.